Sunday, May 29, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Prior COVID-19 protects against subsequent infections

by Medical Finance
in Coronavirus
Study: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19. Image Credit: Noiel / Shutterstock
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

In a recent study published in the Journal of American Medical Association (JAMA), researchers evaluated the duration and level of protection conferred by a coronavirus disease 2019 (COVID-19) infection among non-vaccinated subjects.

In over two years of the COVID-19 pandemic, its etiologic agent, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been extensively studied. In addition, several therapeutics have been designed and implemented, yet the crisis is yet to be effectively controlled.

Throughout the pandemic, various reports have surfaced related to the recurring SARS-CoV-2 infection. While vaccination has effectively lowered disease severity and mortality, many vaccine-breakthrough cases have been reported. Although more than 10 billion vaccine doses have been administered globally, a considerable proportion of the population is yet to be jabbed and is at risk. Given the reports of COVID-19 reinfection, the risk of COVID-19 recurrence in the non-vaccinated population remains poorly defined.

Study: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19. Image Credit: Noiel / ShutterstockStudy: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19. Image Credit: Noiel / Shutterstock

About the study

In the current study, researchers conducted a survival analysis in the United States (US), covering a large population and assessing a natural infection’s immunity among those yet to vaccinate.

Data on SARS-CoV-2-tested patients from 1300 sites across six states in the western US from October 1, 2020, and November 21, 2021, were collected from the Providence health care system. The study included those who were yet to receive a SARS-CoV-2 vaccine and presented symptoms associated with COVID-19 at testing. Patients were monitored from 90 days after the initial positive SARS-CoV-2 result (determined by a positive nucleic acid amplification test or NAAT) for subsequent (re)infection, determined by a positive NAAT and symptom presentation.

Cox proportional hazards regression was carried out to analyze the disease-free survival of COVID-19 cases relative to controls. COVID-19 cases were SARS-CoV-2-positive at initial testing, while controls were SARS-CoV-2-negative on their initial test. The degree of protection associated with COVID-19 infection was calculated for cases relative to controls. The authors calculated a 50-day rolling mean of protection level to measure protection over time and estimated 95% confidence intervals (CIs).

Findings

The research team identified over 24,000 COVID-19 cases and 97,572 controls. The mean age of COVID-19 cases and controls was 42 and 37.7 years, respectively. Females outnumbered males among COVID-19 cases (55.1%) and controls (58.5%).

Overall, 2.8% controls contracted SARS-CoV-2 compared to 0.4% cases. The hazard ratio for developing the disease among cases was 0.15, 0.12 for hospitalization due to COVID-19, and 0.17 for not requiring hospitalization. Previous infection with SARS-CoV-2 was associated with an 85% protection against reinfection, 83% protection against COVID-19 without hospitalization, and 88% protection against COVID-19-related hospitalization. The team observed relatively durable protection with no attenuation during the study period for up to nine months post-initial infection.

Conclusions

To summarize, the team found that non-vaccinated individuals with a previous history of COVID-19 were at 85% lower risk of COVID-19 recurrence than non-vaccinated SARS-CoV-2-naïve subjects. These findings align with earlier reports, which reported around 80% to 100% protection associated with natural immunity.

The observed protection level is comparable to that reported for messenger ribonucleic acid (mRNA)-based COVID-19 vaccines. The 88% and 83% protection observed against hospitalization and non-hospitalization suggested that infection-induced immunity could offer similar protection against mild and severe COVID-19.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

How capable are children to self-swab for SARS-CoV-2?

How capable are children to self-swab for SARS-CoV-2?

by Medical Finance
May 28, 2022
0

Testing for the severe acute respiratory syndrome 2 (SAR-CoV-2) has progressed over the course of the current pandemic and is...

Study: Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study. Image Credit: Vincent B David/Shutterstock

Comparison of breakthrough infections in healthcare workers between 3 and 4-dose BNT162b2 vaccine recipients

by Medical Finance
May 28, 2022
0

The development and mass administration of several coronavirus disease 2019 (COVID-19) vaccines allowed many nations to vaccinate their population. Still,...

Study: Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands. Image Credit: Maridav/Shutterstock

Studying the immune response after COVID-19 vaccination using smartwatches and fitness bands

by Medical Finance
May 29, 2022
0

The response to vaccination varies among individuals. Some vaccines cause adverse reactions, termed reactogenicity. Vaccine reactogenicity can cause physiological changes....

Genome editing in vascular endothelial cells made possible with a powerful new delivery system

Researchers are in the race to beat Omicron

by Medical Finance
May 28, 2022
0

David Veesler and his lab members aren't getting much sleep these days. In the final weeks of 2021, he and...

Study: A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. Image Credit: Huen Structure Bio/Shutterstock

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

by Medical Finance
May 28, 2022
0

When coronavirus disease 2019 (COVID-19) first emerged, healthcare workers were frustrated by the lack of direct treatments for the...

Study: Cardiopulmonary Exercise Performance and Endothelial Function in Convalescent COVID-19 Patients. Image Credit: Drazen Zigic / Shutterstock.com

Researchers investigate loss of fitness following COVID-19

by Medical Finance
May 28, 2022
0

The coronavirus disease 2019 (COVID-19) causes a wide variety of symptoms in infected individuals, the most common of which present...

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Impact of Omicron variant on the response to SARS-CoV-2 mRNA Vaccination in multiple myeloma. Image Credit: David A Litman/Shutterstock
    How effective is mRNA vaccination in multiple myeloma patients?
  • Dialysis 620x480
    All safe for dialysis patients
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply